3月30日 - ** 疫苗生产商 Novavax NVAX.O 股价盘前上涨 1.5% 至 8.58 美元
** 公司任命罗伯特-沃克（Robert Walker）为执行副总裁兼研发主管，立即生效
** 沃克曾任该公司首席医疗官，接替已离职的鲁克桑德拉·德拉吉亚-阿克利（Ruxandra Draghia-Akli）。
** 公司表示，沃克将负责临床前和临床研究，Novavax 将努力推进其疫苗产品线的发展。
** 公司称，沃克在药物和疫苗开发领域拥有 30 多年的经验，曾在美国卫生与公众服务部任职。
** 2025 年股价下跌约 16%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.